Management of glioblastoma

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 18, 2007, Pages 3133-3146

  Aoki, Tomokazu ^a   Hashimoto, Nobuo ^b   Matsutani, Masao ^c  

^a Kitano Hospital   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

chemotherapy; gliadel; glioblastoma; molecular targeted therapy; radiotherapy; surgery; temozolomide; tumour targeted toxin

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; DACARBAZINE; DECANEDIOIC ACID 4,4' (1,3 PROPANEDIYLBIS(OXY))BIS(BENZOIC ACID) COPOLYMER; DECANEDIOIC ACID-4,4'-(1,3-PROPANEDIYLBIS(OXY))BIS(BENZOIC ACID) COPOLYMER; DECANOIC ACID DERIVATIVE; DRUG CARRIER; DRUG DERIVATIVE; POLYESTER; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

BRAIN TUMOR; GENE THERAPY; GLIOBLASTOMA; HUMAN; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; REVIEW;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARMUSTINE; COMBINED MODALITY THERAPY; DACARBAZINE; DECANOIC ACIDS; DRUG CARRIERS; GENE THERAPY; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; POLYESTERS;

EID: 40949132210     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.8.18.3133     Document Type: Review

References (84)

1. FINE HA, DEAR KB, LOEFFLER JS et al : Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (1998) 71:2585-2597.
2. DEANGELIS LM, BURGER PC, GREEN SB et al. : Malignant glioma: who benefi ts from adjuvant chemotherapy? Ann. Neurol. (1998) 44:691-695.
3. STEWART LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet (2002) 359:1011-1018.
4. SAWAYA R: Extent of resection in malignant gliomas: a critical summary. J. Neurooncol. (1999) 42:303-305.
5. LACROIX M, ABI-SAID D, FOURNEY DR et al. : A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. (2001) 95:190-198.
6. LAWS ER, PARNEY IF, HUANG W et al.: Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the glioma outcomes project. J. Neurosurg. (2003) 99:467-473.
7. LITOFSKY NS, BAUER AM, KASPER RS et al. : Image-guided resection of high-grade glioma: patient selection factors and outcome. Neurosurg. Focus (2006) 20:E16.
8. WILLEMS PW, TAPHOORN MJ, BURGER H et al. : Effectiveness of neuronavigation in resecting solitary intracerebral contrast-enhancing tumors: a randomized controlled trial. J. Neurosurg. (2006) 104:360-368.
9. STUMMERW, PICHLMEIER U, MEINEL T et al.: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre Phase III trial. Lancet Oncol. (2006) 7:392-401.
10. WALKER MD, STRIKE TA, SHELINE GE: An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int. J. Radiat Oncol. Biol. Phys. (1979) 5:1725-1731.
11. CHANG CH, HORTON J, SCHOENFELD D et al : Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint radiation therapy oncology group and Eastern cooperative oncology group study. Cancer (1983) 52:997-1007.
12. SOUHAMI L, SEIFERHELD W, BRACHMAN D et al: Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of radiation therapy oncology group 93-05 protocol. Int. J. Radiat. Oncol. Biol. Phys. (2004) 60:853-860.
13. SHAW E, ARUSELL R, SCHEITHAUER B et al.: Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North central cancer treatment group/radiation therapy oncology group/Eastern cooperative oncology group study. J. Clin. Oncol (2002) 20:2267-2276.
14. VAN DEN BENT MJ, AFRA D, DE WITTE O et al : Long-term effi cacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet (2005) 366:985-990.
15. WALKER MD, ALEXANDER E Jr, HUNT WE et al. : Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. (1978) 49:333-343.
16. WALKER MD, GREEN SB, BYAR DP et al : Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. (1980) 303:1323-1329.
17. LEVIN VA, WARA WM, DAVIS RL et al: Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J. Neurosurg. (1985) 63:218-223.
18. BRISMAN R, HOUSEPIAN E, CHANG C, DUFFY P, BALIS E: Adjuvant nitrosourea therapy for glioblastoma. Arch. Neurol. (1976) 33 :745-750.
19. GREEN SB, BYAR DP, WALKER MD et al : Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat. Rep. (1983) 67:121-132.
20. LASSMAN LP, PEARCE GW, GANG J: Sensitivity of intracranial gliomas to vincristine sulphate. Lancet (1965) 17:296-298.
21. CAIRNCROSS JG, MACDONALD DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol. (1988) 23:360-364.
22. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. J. Clin. Oncol. (2001) 19:509-518.
23. TAKAKURA K, ABE H, TANAKA R et al : Effects of ACNU and radiotherapy on malignant glioma. J. Neurosurg. (1986) 64:53-57.
24. MATSUTANI M, NAKAMURA O, NAKAMURA M et al. : Radiation therapy combined with radiosensitizing agents for cerebral glioblastoma in adults. J. Neurooncol (1994) 19:227-237.
25. YOSHIDAJ, KAJITA Y, WAKABAYASHI T et al: Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir. (Wien.) (1994) 127:55-59.
26. HUNCHAREK M, MUSCAT J: Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res. (1998) 18:1303-1311.
27. AOKIT, TAKAHASHIJA, UEBA T et al: Phase II study of nimustine, carboplatin, vincristine, and interferon-fJ with radiotherapy for glioblastoma multiforme: experience of the Kyoto neuro-oncology group. J. Neurosurg. (2006) 105:385-391.
28. WELLER M, MULLER B, KOCH R et al : Neuro-oncology working group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-fi eld radiotherapy in the fi rst-line treatment of malignant glioma. J. Clin. Oncol. (2003) 21:3276-3284.
29. BRIZEL DM, ALBERS ME, FISHER SR et al : Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. (1998) 338:1798-1804.
30. DEWIT L: Combined treatment of radiation and cis-diamminedichloroplatinum (II): a review of experimental and clinical data. Int. J. Radiat. Oncol. Biol. Phys. (1987) 13:403-426.
31. RAJKUMAR SV, BUCKNERJC, SCHOMBERG PJ et al : Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. Int. J. Radiat. Oncol. Biol. Phys. (1998) 42:969-975.
32. GILBERT M, O'NEILL A, GROSSMAN S et al : A Phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: an Eastern cooperative oncology group study (E2393). J. Neurooncol. (2000) 47:145-152.
33. GROSSMAN SA, O'NEILL A, GRUNNET M et al. : Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern cooperative oncology group trial 2394. J. Clin. Oncol. (2003) 21:1485-1491.
34. BUCKNERJC, BALLMAN KV, MICHALAK JC et al : Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North central cancer treatment group 93-72-52 and southwest oncology group 9503 trials. J. Clin. Oncol. (2006) 24:3871-3879.
35. AOKI T, NISHIKAWA R, MIZUTANIT et al : Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas-fi rst study in Asians. Int. J. Clin. Oncol. (2007) 12(5):341-349.
36. BRADA M, JUDSON I, BEALE P et al: Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br. J. Cancer (1999) 81:1022-1030.
37. BEALE P, JUDSON I, MOORE S et al. : Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. Cancer Chemother. Pharmacol. (1999) 44:389-394.
38. HAMMOND LA, ECKARDTJR, BAKER SD et al. : Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J. Clin. Oncol. (1999) 17:2604-2613.
39. STUPP R, MASON WP, VAN DEN BENT MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. (2005) 352:987-996.
40. DEANGELIS LM: Chemotherapy for brain tumors-a new beginning. N. Engl. J. Med. (2005) 352:1036-1038.
41. ROA W, BRASHER PM, BAUMAN G et al. : Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J. Clin. Oncol. (2004) 22:1583-1588.
42. CHINOT OL, BARRIE M, FRAUGER E et al. : Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer (2004) 100:2208-2214.
43. BRANDES AA, VASTOLA F, BASSO U et al. : A prospective study on glioblastoma in the elderly. Cancer (2003) 97:657-662.
44. HEGI ME, DISERENS AC, GORLIA T et al: MGMT gene silencing and benefi t from temozolomide in glioblastoma. N. Engl. J. Med. (2005) 352:997-1003.
45. TOLCHERAW, GERSON SL, DENIS L et al. : Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer (2003) 88:1004-1011.
46. WICK W, STEINBACH JP, KUKER WM et al. : One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology (2004) 62:2113-2115.
47. BRANDES AA, TOSONI A, CAVALLO G et al.: Temozolomide 3 weeks on and 1 week off as fi rst-line therapy for recurrent glioblastoma: Phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br. J. Cancer (2006) 95:1155-1160.
48. BROCK CS, NEWLANDS ES, WEDGE SR et al. : Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. (1998) 58:4363-4367.
49. VERA K, DJAFARI L, FAIVRE S et al.: Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. Ann. Oncol. (2004) 15:161-171.
50. SPIRO TP, LIU L, MAJKA S et al.: Temozolomide: the effect of once-and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin. Cancer Res. (2001)7:2309-2317.
51. CAIRNCROSS G, BERKEYB, SHAW E et al : Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J. Clin. Oncol. (2006) 24:2707-2714.
52. VAN DEN BENT MJ, CARPENTIER AF, BRANDES AA et al.: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European organisation for research and treatment of cancer Phase III trial. J. Clin. Oncol. (2006) 24:2715-2722.
53. VAN DEN BENT MJ, TAPHOORN MJ, BRANDES AA et al. : Phase II study of fi rst-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European organization for research and treatment of cancer brain tumor group study 26971. J. Clin. Oncol. (2003) 21:2525-2528.
54. BRADA M, VIVIERS L, ABSON C et al.: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann. Oncol. (2003) 14:1715-1721.
55. HERRLINGER U, RIEGER J, KOCH D et al. : Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J. Clin. Oncol. (2006) 24:4412-4417.
56. NATSUME A, ISHII D, WAKABAYASHI T et al.: IFN-β down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. (2005) 65:7573-7579.
57. RAIZER JJ, MALKIN MG, KLEBER M et al. : Phase I study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Neurooncology (2004) 6:247-252.
58. BALANA C, LOPEZ-POUSA A, BERROCAL A et al. : Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish medical neuro-oncology group (GENOM). J. Neurooncol. (2004) 70:359-369.
59. BRANDES AA, BASSO U, RENI M et al.: First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a Phase II study of the gruppo italiano cooperativo di neuro-oncologia. J. Clin. Oncol. (2004) 22:1598-1604.
60. CHANG SM, LAMBORN KR, MALEC M et al. : Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. (2004) 60:353-357.
61. BUTOWSKI N, PRADOS MD, LAMBORN KR et al. : A Phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. (2005) 61:1454-1459.
62. SPENCE AM, PETERSON RA, SCHARNHORST JD et al. : Phase II study of concurrent continuous temozolomide (TMZ) and tamoxifen (TMX) for recurrent malignant astrocytic gliomas. J. Neurooncol. (2004) 70:91-95.
63. QUINN JA, DESJARDINS A, WEINGART J et al. : Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol. (2005) 23:7178-7187.
64. GROVES MD, PUDUVALLIVK, HESS KR et al. : Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. (2002) 20:1383-1388.
65. JAECKLE KA, HESS KR, YUNG WK et al. : Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American brain tumor consortium study. J. Clin. Oncol. (2003) 21:2305-2311.
66. BREM H, PIANTADOSI S, BURGER PC et al : Placebo-controlled trial of safety and effi cacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet (1995) 345:1008-1012.
67. WESTPHAL M, HILT DC, BORTEY E et al : A Phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncology (2003) 5:79-88.
68. FUNG LK, EWEND MG, SILLS A et al : Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res. (1998) 58:672-684.
69. GURURANGAN S, COKGOR L, RICH JN et al : Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neurooncology (2001) 3:246-250.
70. LIMENTANI SA, ASHERA, HEAFNER M et al. : A Phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J. Neurooncol. (2005) 72:241-244.
71. SAMPSON JH, AKABANI G, ARCHER GE et al. : Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol. (2003) 65:27-35.
72. PARNEY IF, KUNWAR S, MCDERMOTT M et al.: Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J. Neurosurg. (2005) 102:267-275.
73. WEAVER M, LASKE DW: Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neurooncol. (2003) 65:3-13.
74. RAINOV NG, HEIDECKE V: Long-term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001). J. Neurooncol. (2004) 66:197-201.
75. OHGAKI H, DESSEN P, JOURDE B et al. : Genetic pathways to glioblastoma: a population-based study. Cancer Res. (2004) 64:6892-6899.
76. REARDON DA, EGORIN MJ, QUINN JA et al. : Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol. (2005) 23:9359-9368.
77. FINE HA L, KIM C, ROYCE D et al.: Thornton results from Phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2005) 23 (S16) (1 Suppl.):1504.
78. VREDENBURGH JJ, DESJARDINS A, HERNDON JE II et al. : Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. (2007) 13:1253-1259.
79. MELLINGHOFF IK, WANG MY, VIVANCO I et al. : Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. (2005) 353:2012-2024.
80. GALANIS E, BUCKNER JC, MAURER MJ et al. : Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North central cancer treatment group study. J. Clin. Oncol. (2005) 23:5294-5304.
81. FINE HA: Toward a glioblastoma vaccine: promise and potential pitfalls. J. Clin. Oncol. (2004) 22:4240-4243.
82. YU JS, LIU G, YING H et al.: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specifi c, cytotoxic T-cells in patients with malignant glioma. Cancer Res. (2004) 64:4973-4979.
83. STEINER HH, BONSANTO MM, BECKHOVE P et al.: Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefi t. J. Clin. Oncol. (2004) 22:4272-4281.
84. YAJIMA N, YAMANAKA R, MINE T et al. : Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin. Cancer Res. (2005) 11:5900-5911.